Anebulo Pharmaceuticals Inc. (ANEB)
OTC PINK OTC PINK Primary Summary
Anebulo Pharmaceuticals Inc. (ANEB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anebulo Pharmaceuticals Inc. ever had a stock split?
Anebulo Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard Anthony Cunningham CEO | OTC PINK Exchange | 034569103 CUSIP |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm focusing on developing treatments for patients suffering from acute cannabinoid intoxication (ACI) and substance addiction. Founded in 2020, the company is headquartered in Lakeway, Texas. It aims to fulfill the unmet medical needs of individuals experiencing ACI, providing a dedicated approach towards developing pharmaceutical interventions for cannabinoid-related health issues.
Products and Services
- ANEB-001
Anebulo Pharmaceuticals, Inc.'s flagship product candidate, ANEB-001, is a pioneering small molecule cannabinoid receptor antagonist. Currently undergoing a Phase II clinical trial, ANEB-001 is designed as a specific antidote for acute cannabinoid intoxication, a rapidly emerging medical concern due to the increasing availability and consumption of cannabinoid products. By blocking the effects of cannabinoids at the receptor level, ANEB-001 has the potential to provide immediate relief for patients experiencing ACI, thereby addressing a significant gap in current treatment paradigms.
